FDA must continue to inspect contractors involved in SARS-CoV-2 injections—it's our last bastion of hope
Quality issues with SARS-CoV-2 injections are mounting
Quality issues with SARS-CoV-2 injections are mounting
Yesterday, I covered an article in FiercePharma titled: Moderna's new booster launch tripped up by production issues at Catalent plant.
The full account can be found here:
The shocking revelation in the article was that there was an extensive catalogue of non-compliances with the legal obligations pla…
Keep reading with a 7-day free trial
Subscribe to INSIDE PHARMA to keep reading this post and get 7 days of free access to the full post archives.